Pfizer requests EUA for oral COVID-19 antiviral treatment
Pfizer today announced its formal request that the Food and Drug Administration authorize the emergency use of its PAXLOVID (PF-07321332; ritonavir) oral antiviral for combating SARS-CoV-2. Pfizer says data from its phase 2/3 clinical trial shows that the drug, which works as a 3CL protease inhibitor, reduced the risk of COVID-19-related hospitalization or death by 89%.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…